SCHEMBL4833952

SCHEMBL4833952

NC1=c2ccoc2=NCN1c1ccc(NS(=O)(=O)Cc2cc(C(F)(F)F)ccc2Cl)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRAP1 Q12931 3/20 0.35
▸ CSF1R P07333 1/20 0.34
▸ SCN9A Q15858 2/20 0.32
▸ CA1 P00915 2/20 0.32
▸ CA2 P00918 2/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ GLA P06280 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ KIF11 P52732 2/20 0.31
▸ NPY5R Q15761 1/20 0.31
▸ HSP90AA1 P07900 1/20 0.31
▸ HSP90B1 P14625 1/20 0.31
▸ SGK1 O00141 1/20 0.31
▸ ABL1 P00519 1/20 0.31
▸ CA12 O43570 1/20 0.30
▸ CA9 Q16790 1/20 0.30
▸ EPHX2 P34913 1/20 0.30
▸ AVPR2 P30518 1/20 0.30
▸ GPR27 Q9NS67 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4833428 0.91 SGK1 (0.36) CSF1RCA1CA2KIF11NPY5R
SCHEMBL4834122 0.81 PFKFB4 (0.38) SCN9ACA1CA2LMNANPY5R
SCHEMBL4831000 0.81 NPY5R (0.45) CA1CA2ALDH1A1LMNAKIF11
SCHEMBL4833691 0.78 PSEN1 (0.44) LMNANPY5R
SCHEMBL4830823 0.78 RIPK1 (0.49) CA1CA2ALDH1A1LMNAL3MBTL1
SCHEMBL4833966 0.76 NAMPT (0.38) ALDH1A1LMNAL3MBTL1SGK1
SCHEMBL4833569 0.76 TYMS (0.44) ALDH1A1LMNAL3MBTL1KIF11NPY5R
SCHEMBL4836406 0.76 RORC (0.34) CA1CA2ALDH1A1LMNA
SCHEMBL4829022 0.76 MAPT (0.49) ALDH1A1LMNAPTGS2
SCHEMBL4827030 0.75 ALDH1A1 (0.47) ALDH1A1LMNAL3MBTL1SGK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 — — US claimed
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US claimed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP claimed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO claimed
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 — — US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 — — US disclosed
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US disclosed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP disclosed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004142-A1 Chemical compounds TIE1, KDR, TEK TRAP1 1819/4885CSF1R 807/4885SCN9A 4860/4885
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF TIE1, TEK, KDR TRAP1 3438/4885CSF1R 1346/4885SCN9A 4833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback